Effects of Cycloheximide on B-CLL and Normal Lymphocytes
Author Information
Author(s): R.J. Collins, B.V. Harmon, T. Souvlis, J.H. Pope, J.F.R. Kerr
Primary Institution: Royal Brisbane Hospital; University of Queensland Medical School; Sir Albert Sakzewski Virus Research Laboratory
Hypothesis
The study examines the effect of the protein synthesis inhibitor cycloheximide on apoptosis in B-chronic lymphocytic leukaemia (B-CLL) cells and normal lymphocytes.
Conclusion
Cycloheximide treatment increased apoptosis in B-CLL cells and normal lymphocytes in a dose-dependent manner.
Supporting Evidence
- CHM treatment augmented apoptosis in B-CLL cultures in a dose-dependent manner.
- Normal lymphocytes showed increased apoptosis at higher concentrations of CHM.
- DNA fragmentation patterns characteristic of apoptosis were observed in B-CLL cells treated with CHM.
Takeaway
This study found that a drug called cycloheximide can make certain blood cells die more easily, which is important for understanding how to treat blood cancers.
Methodology
The study involved culturing B-CLL cells and normal lymphocytes with varying concentrations of cycloheximide and measuring apoptosis through microscopy and DNA analysis.
Limitations
The study could not distinguish between spontaneous apoptosis and that induced by cycloheximide in treated cultures.
Participant Demographics
Eight patients with B-CLL and nine healthy laboratory personnel.
Statistical Information
P-Value
0.0008
Statistical Significance
p=0.0008
Want to read the original?
Access the complete publication on the publisher's website